Harrow, Inc. HROW
Regular-session close
After hours · Nov 19, 5:06 PM ET
- YTD
- -34.43%
- 1 year
- -18.86%
5D +3.01 (+10.43%)
- Market cap
- 1.21B
- Revenue (ttm)
- 303.25M
- Profit margin
- -9.39%
- EPS (ttm)
- -0.76
- Shares out
- 37.53M
- Forward P/E
- 17.18
- YTD return
- -34.43%
- 1-year return
- -18.86%
- 50-day average
- 30.31
- 200-day average
- 37.30
- Volume
- 761.81K
- Avg volume
- 614.37K
- Open
- 32.00
- Previous close
- 32.16
- Day's range
- 31.39 – 32.47
- 52-week range
- 25.76 – 54.85
- Beta
- 0.17
- Analysts
- Strong Buy
- Price target
- 62.25 (+93.7%)
- Earnings date
- Mar 1, 2027
Key statistics
- Enterprise value
- 1.43B
- Price / sales
- 3.98
- Price / book
- 41.30
- Revenue growth
- 38.60%
- Free cash flow
- -34.20M
- Total cash
- 76.81M
- Total debt
- 300.86M
- Return on equity
- -75.47%
- Short % of float
- 21.03%
Fundamental scorecard
5 of 25 checks passed on HROW’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 42.00
- Target (mean)
- 62.25
- Target (high)
- 88.00
- Strong buy0
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate 0.2975.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | 0.56 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | 0.1944 | 0.25 | +0.06 | +28.60% |
| Aug 10, 2026 | Jun 30, 2026 | -0.17875 | -0.46 | -0.28 | -157.34% |
| May 11, 2026 | Mar 31, 2026 | -0.43 | -0.74 | -0.31 | -72.09% |
| Mar 2, 2026 | Dec 31, 2025 | 0.40 | 0.18 | -0.22 | -55.00% |
| Nov 10, 2025 | Sep 30, 2025 | 0.22 | 0.03 | -0.19 | -86.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | BTIG | reit | Buy | Buy |
| Oct 7, 2026 | BTIG | reit | Buy | Buy |
| Sep 9, 2026 | Leerink Partners | init | — | Outperform |
| Aug 11, 2026 | BTIG | reit | Buy | Buy |
| Jul 21, 2026 | BTIG | reit | Buy | Buy |
| May 13, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- harrow.com
News
Harrow: Strong Revenue Growth And Operating Leverage Ahead
66,773 Shares of Harrow, Inc. $HROW Bought by Drive Wealth Management LLC
Harrow to Participate in Two Investor Conferences in November
AAON, Ziprecruiter, Rackspace Technology, Babcock & Wilcox And Other Big Stocks Moving Higher On Tuesday
Harrow Q3 2026 Earnings Call Transcript
12 Health Care Stocks Moving In Tuesday's Pre-Market Session Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $349.747M Est
Harrow Q3 EPS $0.25 Beats $0.22 Estimate, Sales $99.297M Beat $98.501M Estimate
Your note
Sign in to keep a note on HROW — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUM MARK L | Chief Executive Officer | Purchase | May 13, 2026 | 2,996,130 |
| BOLL ANDREW R | President | Purchase | May 13, 2026 | 814,679 |
| GRAVES ADRIENNE L | Director | Purchase | May 17, 2026 | 1,000 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 3, 2026 | 0 |
| SAHAREK JOHN P | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 2, 2025 | 467,388 |
| SHOJAEI AMIR | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.88% | 2,956,373 | 94.99M | Sep 29, 2026 |
| Opaleye Management Inc. | 5.61% | 2,105,000 | 67.63M | Sep 29, 2026 |
| Private Capital Management, LLC | 4.44% | 1,665,445 | 53.51M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.72% | 1,394,734 | 44.81M | Sep 29, 2026 |
| Deep Track Capital, Lp | 2.85% | 1,069,000 | 34.35M | Sep 29, 2026 |
| State Street Corporation | 2.73% | 1,024,839 | 32.93M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,001,445 | 32.18M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.23% | 836,793 | 26.89M | Sep 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.53% | 576,069 | 18.51M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.25% | 470,121 | 15.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.02% | 383,781 | 12.33M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.94% | 354,362 | 11.39M | Aug 30, 2026 |
